AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 34222067 — intervention group
Group type: COMPARATOR
Intervention: Control (education materials only)
Number of subjects: 77
Study 32721104 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotinamide (1.5 g/day for 6 weeks, then 3.0 g/day for 6 weeks)
Number of subjects: 57
Study 32721104 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 57
Study 34802729 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupivacaine liposome suspension block, oral placebo (BUP)
Number of subjects: 50
Study 34802729 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine block, oral placebo (LID)
Number of subjects: 50
Study 34802729 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine block, oral meloxicam (1 mg/kg of body weight; LID + MEL)
Number of subjects: 50
Study 34802729 — intervention group
Group type: COMPARATOR
Intervention: Saline block, oral placebo (CON)
Number of subjects: 50
Study 34802729 — intervention group
Group type: EXPERIMENTAL
Intervention: Saline block, oral placebo, sham dehorn (SHAM)
Number of subjects: 50
Study 33055009 — intervention group
Group type: EXPERIMENTAL
Intervention: Health education program consisting of six educational sessions over 45 days
Number of subjects: 80
Study 33055009 — intervention group
Group type: COMPARATOR
Intervention: Routine diabetic care at the clinic
Number of subjects: 80
Study 33220141 — intervention group
Group type: EXPERIMENTAL
Intervention: Bonding agent (Adper™ Single Bond 2, 3M ESPE) applied before sealant application (Helioseal®clear, Ivoclar Vivadent)
Number of subjects: 98
Study 33220141 — intervention group
Group type: COMPARATOR
Intervention: Nonbonded sealants
Number of subjects: 98
Study 33220141 — intervention group
Group type: EXPERIMENTAL
Intervention: Bonded and nonbonded sealants
Number of subjects: 98
Study 33352676 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based resistance training (EXE)
Number of subjects: 9
Study 33352676 — intervention group
Group type: COMPARATOR
Intervention: Control group (CON)
Number of subjects: 9
Study 35449008 — intervention group
Group type: EXPERIMENTAL
Intervention: STRONG programme (≥6 weekly sessions with patient education, motivational and pharmaceutical support)
Number of subjects: 42
Study 35449008 — intervention group
Group type: EXPERIMENTAL
Intervention: STRONG programme
Number of subjects: 42
Study 35449008 — intervention group
Group type: COMPARATOR
Intervention: Usual care (standard care)
Number of subjects: 42
Study 36383389 — intervention group
Group type: EXPERIMENTAL
Intervention: 1-day Nordic hamstring exercise training (n = 16)
Number of subjects: 45
Study 36383389 — intervention group
Group type: EXPERIMENTAL
Intervention: 2-day Nordic hamstring exercise training (n = 15)
Number of subjects: 45
Study 36383389 — intervention group
Group type: COMPARATOR
Intervention: Control group (n = 14)
Number of subjects: 45
Study 33780423 — intervention group
Group type: EXPERIMENTAL
Intervention: NeuroEPO (1 mL, at a concentration of 1 mg/mL) administered intranasally once a week for 5 weeks
Number of subjects: 26
Study 33780423 — intervention group
Group type: COMPARATOR
Intervention: Placebo administered intranasally once a week for 5 weeks
Number of subjects: 26
Study 32188427 — intervention group
Group type: EXPERIMENTAL
Intervention: Poor knowledge regarding hepatitis
Number of subjects: 504
Study 32188427 — intervention group
Group type: EXPERIMENTAL
Intervention: Unhygienic sanitary practices
Number of subjects: 504
Study 32188427 — intervention group
Group type: EXPERIMENTAL
Intervention: Unhygienic practices related to drinking water
Number of subjects: 504
Study 32188427 — intervention group
Group type: EXPERIMENTAL
Intervention: Residing in urban areas
Number of subjects: 504
Study 32188427 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower family income
Number of subjects: 504
Study 35353167 — intervention group
Group type: EXPERIMENTAL
Intervention: Tacrolimus
Number of subjects: 314
Study 35353167 — intervention group
Group type: COMPARATOR
Intervention: IVCY
Number of subjects: 314
Study 33468072 — intervention group
Group type: EXPERIMENTAL
Intervention: Safer conception methods (SCM)
Number of subjects: 389
Study 33468072 — intervention group
Group type: EXPERIMENTAL
Intervention: Modern contraceptive use
Number of subjects: 389
Study 32220524 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketamine sedation with local anesthesia
Number of subjects: 47
Study 32220524 — intervention group
Group type: COMPARATOR
Intervention: Ketamine sedation without local anesthesia
Number of subjects: 47
Study 33663737 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower Dose Edoxaban Regimen (LDER) - 30 mg once daily (dose reduced to 15 mg in selective patients)
Number of subjects: 14014
Study 33663737 — intervention group
Group type: COMPARATOR
Intervention: Higher Dose Edoxaban Regimen (HDER) - 60 mg once daily (dose reduced to 30 mg in selective patients)
Number of subjects: 14014
Study 33663737 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower Dose Edoxaban Regimen (LDER)
Number of subjects: 14014
Study 32403113 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical corticosteroids
Number of subjects: 61
Study 32403113 — intervention group
Group type: EXPERIMENTAL
Intervention: UVA1
Number of subjects: 61
Study 32403113 — intervention group
Group type: EXPERIMENTAL
Intervention: PUVA
Number of subjects: 61
Study 32403113 — intervention group
Group type: EXPERIMENTAL
Intervention: Intralesional triamcinolone acetonide
Number of subjects: 61
Study 32403113 — intervention group
Group type: EXPERIMENTAL
Intervention: First-line therapy
Number of subjects: 61
Study 32403113 — intervention group
Group type: EXPERIMENTAL
Intervention: Second-line therapy
Number of subjects: 61
Study 32403113 — intervention group
Group type: EXPERIMENTAL
Intervention: Third-line therapy
Number of subjects: 61
Study 35699953 — intervention group
Group type: EXPERIMENTAL
Intervention: HPVCF + usual care
Number of subjects: 375
Study 35699953 — intervention group
Group type: COMPARATOR
Intervention: usual care only
Number of subjects: 375
Study 33757440 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant FOLFIRINOX chemotherapy (8 cycles) followed by surgery without adjuvant treatment (arm A)
Number of subjects: 368
Study 33757440 — intervention group
Group type: COMPARATOR
Intervention: Neoadjuvant gemcitabine with hypofractionated radiotherapy (36 Gy in 15 fractions) during the second cycle, followed by surgery and 4 cycles of adjuvant gemcitabine (arm B)
Number of subjects: 368
Study 33757440 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant FOLFIRINOX chemotherapy
Number of subjects: 368
Study 33757440 — intervention group
Group type: COMPARATOR
Intervention: Neoadjuvant gemcitabine with hypofractionated radiotherapy
Number of subjects: 368
Study 35320365 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgery
Number of subjects: 316
Study 35320365 — intervention group
Group type: COMPARATOR
Intervention: Medical/lifestyle intervention
Number of subjects: 316
Study 32899447 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin C supplementation (1000 mg daily) during the first six weeks of training.
Number of subjects: 15
Study 32899447 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin C supplementation (1000 mg daily) during the second six weeks of training.
Number of subjects: 15
Study 32899447 — intervention group
Group type: COMPARATOR
Intervention: Training without vitamin C supplementation (first six weeks).
Number of subjects: 15
Study 32899447 — intervention group
Group type: EXPERIMENTAL
Intervention: Training with vitamin C supplementation (last six weeks).
Number of subjects: 15
Study 35508695 — intervention group
Group type: EXPERIMENTAL
Intervention: AZA-7
Number of subjects: 187
Study 35508695 — intervention group
Group type: COMPARATOR
Intervention: AZA-5
Number of subjects: 187
Study 34500184 — intervention group
Group type: EXPERIMENTAL
Intervention: Lithium
Number of subjects: 592
Study 34500184 — intervention group
Group type: EXPERIMENTAL
Intervention: Quetiapine
Number of subjects: 592
Study 34500184 — intervention group
Group type: EXPERIMENTAL
Intervention: Additional mood-stabilizing treatment
Number of subjects: 592
Study 32113882 — intervention group
Group type: EXPERIMENTAL
Intervention: Autonomous exercise plan
Number of subjects: 69
Study 34725773 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutrition only (NUTR, n=16)
Number of subjects: 56
Study 34725773 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutrition plus exercise (NUTR+EX, n=21)
Number of subjects: 56
Study 34725773 — intervention group
Group type: COMPARATOR
Intervention: Exercise only (EX, n=19)
Number of subjects: 56
Study 33237672 — intervention group
Group type: COMPARATOR
Intervention: Randomized Controlled Trials (RCTs)
Number of subjects: 23
Study 33237672 — intervention group
Group type: COMPARATOR
Intervention: Non-Randomized Trials
Number of subjects: 23
Study 33237672 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall Clinical Trials
Number of subjects: 23
Study 33237672 — intervention group
Group type: COMPARATOR
Intervention: Q1 Journals
Number of subjects: 23
Study 33237672 — intervention group
Group type: COMPARATOR
Intervention: Q2 and Q3 Journals
Number of subjects: 23
Study 33237672 — intervention group
Group type: COMPARATOR
Intervention: Last 2 Decades
Number of subjects: 23
Study 34701692 — intervention group
Group type: EXPERIMENTAL
Intervention: Group B (experimental group) - auto-positioning with LINAC and SGRT system
Number of subjects: 40
Study 34701692 — intervention group
Group type: COMPARATOR
Intervention: Group A (control group) - manual alignment based on skin marking
Number of subjects: 40
Study 36189646 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral extended-release nifedipine 30 mg every 24 hours
Number of subjects: 110
Study 36189646 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 110
Study 35896614 — intervention group
Group type: EXPERIMENTAL
Intervention: Micro enemas delivered by the squeeze-tube method
Number of subjects: 20
Study 35896614 — intervention group
Group type: COMPARATOR
Intervention: Micro enemas delivered by the catheter method
Number of subjects: 20
Study 34212461 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-Violent Resistance adapted for MID (NVR-MID)
Number of subjects: 124
Study 34861125 — intervention group
Group type: EXPERIMENTAL
Intervention: Guided mindfulness meditation (postoperative days 0-3)
Number of subjects: 45
Study 34861125 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 45
Study 34861125 — intervention group
Group type: EXPERIMENTAL
Intervention: Guided mindfulness meditation
Number of subjects: 45
Study 34961950 — intervention group
Group type: EXPERIMENTAL
Intervention: Ticagrelor 90 mg twice daily
Number of subjects: 250
Study 34961950 — intervention group
Group type: COMPARATOR
Intervention: Aspirin 81 mg twice daily
Number of subjects: 250
Study 32139222 — intervention group
Group type: EXPERIMENTAL
Intervention: High DAPT score (≥2)
Number of subjects: 11289
Study 32139222 — intervention group
Group type: COMPARATOR
Intervention: Low DAPT score (<2)
Number of subjects: 11289
Study 32139222 — intervention group
Group type: EXPERIMENTAL
Intervention: Ticagrelor monotherapy
Number of subjects: 11289
Study 32139222 — intervention group
Group type: COMPARATOR
Intervention: Aspirin monotherapy
Number of subjects: 11289
Study 35948866 — intervention group
Group type: EXPERIMENTAL
Intervention: SES-sensitive implementation strategy with additional face-to-face guidance by GP nurses
Number of subjects: 0
Study 35948866 — intervention group
Group type: COMPARATOR
Intervention: All-SES implementation strategy
Number of subjects: 0
Study 32750538 — intervention group
Group type: EXPERIMENTAL
Intervention: Azithromycin MDA
Number of subjects: 293
Study 36260469 — intervention group
Group type: EXPERIMENTAL
Intervention: Silorane resin composite
Number of subjects: 192
Study 36260469 — intervention group
Group type: COMPARATOR
Intervention: Glass ionomer cement (GIC)
Number of subjects: 192
Study 33825030 — intervention group
Group type: EXPERIMENTAL
Intervention: FFP2/N95 mask
Number of subjects: 13
Study 33825030 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical mask
Number of subjects: 13
Study 33825030 — intervention group
Group type: COMPARATOR
Intervention: No mask (control)
Number of subjects: 13
Study 34958123 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 mg b.i.d. enoxaparin
Number of subjects: 183
Study 34958123 — intervention group
Group type: COMPARATOR
Intervention: 40 mg o.d. enoxaparin
Number of subjects: 183
Study 34434546 — intervention group
Group type: EXPERIMENTAL
Intervention: Synbiotic supplementation
Number of subjects: 16
Study 34434546 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 32286883 — intervention group
Group type: EXPERIMENTAL
Intervention: BiOSS stent
Number of subjects: 0
Study 32286883 — intervention group
Group type: COMPARATOR
Intervention: Regular drug-eluting stent
Number of subjects: 0
Study 34045137 — intervention group
Group type: EXPERIMENTAL
Intervention: Asymmetrical polyethylene insert
Number of subjects: 33
Study 34045137 — intervention group
Group type: COMPARATOR
Intervention: Symmetrical polyethylene insert
Number of subjects: 33
Study 34081712 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-affirmation intervention during the first meeting with a caseworker
Number of subjects: 174
Study 36457363 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive multisensory rehabilitation (CMR) for 6 weeks followed by 6 weeks of standard of care (no therapy) at home
Number of subjects: 299000
Study 36457363 — intervention group
Group type: COMPARATOR
Intervention: Standard of care (no therapy) for 6 weeks followed by 6 weeks of CMR
Number of subjects: 299000
Study 32482335 — intervention group
Group type: EXPERIMENTAL
Intervention: sweet taste moisturizing gel
Number of subjects: 56
Study 32482335 — intervention group
Group type: EXPERIMENTAL
Intervention: acid taste with Japanese apricot extract moisturizing gel
Number of subjects: 56
Study 32482335 — intervention group
Group type: EXPERIMENTAL
Intervention: Japanese apricot scent moisturizing gel
Number of subjects: 56
Study 32482335 — intervention group
Group type: EXPERIMENTAL
Intervention: acid taste with citric acid moisturizing gel
Number of subjects: 56
Study 32482335 — intervention group
Group type: EXPERIMENTAL
Intervention: tasteless and odorless moisturizing gel
Number of subjects: 56
Study 32482335 — intervention group
Group type: COMPARATOR
Intervention: control (no gel administered)
Number of subjects: 56
Study 33566432 — intervention group
Group type: EXPERIMENTAL
Intervention: Imiquimod 3.75%
Number of subjects: 9
Study 33566432 — intervention group
Group type: COMPARATOR
Intervention: MAL-PDT (5-aminolaevulinic acid)
Number of subjects: 9
Study 33566432 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 9
Study 35110310 — intervention group
Group type: EXPERIMENTAL
Intervention: Advanced Hybrid Closed Loop (AHCL) system (MiniMed 670G version 4.0)
Number of subjects: 124
Study 35110310 — intervention group
Group type: COMPARATOR
Intervention: MDI plus IS‐CGM
Number of subjects: 124
Study 33639517 — intervention group
Group type: EXPERIMENTAL
Intervention: Auricular point acupressure treatment (acupressure points with Cowherb seeds)
Number of subjects: 60
Study 33639517 — intervention group
Group type: COMPARATOR
Intervention: Sham auricular therapy (acupressure points without Cowherb seeds)
Number of subjects: 60
Study 33639517 — intervention group
Group type: EXPERIMENTAL
Intervention: Auricular point acupressure treatment
Number of subjects: 60
Study 33639517 — intervention group
Group type: COMPARATOR
Intervention: Sham auricular therapy
Number of subjects: 60
Study 32289190 — intervention group
Group type: EXPERIMENTAL
Intervention: guselkumab
Number of subjects: 130
Study 32289190 — intervention group
Group type: COMPARATOR
Intervention: adalimumab
Number of subjects: 130
Study 35958172 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D supplementation (1,000 IU/day for children < 1 year; 2,000 IU/day for children 1-17 years)
Number of subjects: 45
Study 35958172 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D supplementation
Number of subjects: 45
Study 35958172 — intervention group
Group type: COMPARATOR
Intervention: Control (standard of care)
Number of subjects: 45
Study 34215606 — intervention group
Group type: EXPERIMENTAL
Intervention: Traditional Chinese medicine (TCM) treatment, specific intervention details not provided.
Number of subjects: 0
Study 36121242 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-expanding (SE) Evolut PRO/PRO+
Number of subjects: 2241
Study 36121242 — intervention group
Group type: COMPARATOR
Intervention: Balloon-expandable (BE) Sapien 3 ULTRA
Number of subjects: 2241
Study 33054825 — intervention group
Group type: EXPERIMENTAL
Intervention: Five-session manual-based group intervention for siblings and parents of children with neurodevelopmental disorders.
Number of subjects: 288
Study 33054825 — intervention group
Group type: COMPARATOR
Intervention: 12-week waitlist control group.
Number of subjects: 288
Study 33539268 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultra-Long-Toss (ULT)
Number of subjects: 24
Study 33539268 — intervention group
Group type: EXPERIMENTAL
Intervention: Straight-Line Long-Toss (SLT)
Number of subjects: 24
Study 33539268 — intervention group
Group type: COMPARATOR
Intervention: Comparison of ULT and SLT
Number of subjects: 24
Study 34151734 — intervention group
Group type: EXPERIMENTAL
Intervention: POST intervention (personalized Survivorship Care Plan)
Number of subjects: 200
Study 34151734 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual
Number of subjects: 200
Study 32807537 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified Bilateral Clamshell Thoracotomy (MCT)
Number of subjects: 15
Study 32807537 — intervention group
Group type: COMPARATOR
Intervention: Left Anterolateral Thoracotomy (LAT)
Number of subjects: 15
Study 34999670 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined thoracic paravertebral block (TPVB) and general anesthesia
Number of subjects: 86
Study 34999670 — intervention group
Group type: COMPARATOR
Intervention: General anesthesia alone
Number of subjects: 86
Study 33264578 — intervention group
Group type: EXPERIMENTAL
Intervention: Select-by-audiogram
Number of subjects: 37
Study 33264578 — intervention group
Group type: EXPERIMENTAL
Intervention: Select-by-self-test
Number of subjects: 37
Study 33264578 — intervention group
Group type: EXPERIMENTAL
Intervention: Select-by-trying
Number of subjects: 37
Study 33264578 — intervention group
Group type: EXPERIMENTAL
Intervention: Select-by-questionnaire
Number of subjects: 37
Study 33264578 — intervention group
Group type: EXPERIMENTAL
Intervention: Random assignment
Number of subjects: 37
Study 33264578 — intervention group
Group type: COMPARATOR
Intervention: NAL-NL2 condition
Number of subjects: 37
Study 36100964 — intervention group
Group type: EXPERIMENTAL
Intervention: 3-dimensional-printed resection guide
Number of subjects: 62
Study 36100964 — intervention group
Group type: COMPARATOR
Intervention: Control (no resection guide)
Number of subjects: 62
Study 32075569 — intervention group
Group type: EXPERIMENTAL
Intervention: Indwelling urinary catheter (IUC) use within seven days post-randomization
Number of subjects: 11093
Study 32075569 — intervention group
Group type: COMPARATOR
Intervention: Control group (no IUC use)
Number of subjects: 11093
Study 32075569 — intervention group
Group type: EXPERIMENTAL
Intervention: Indwelling urinary catheter (IUC) use
Number of subjects: 11093
Study 32945020 — intervention group
Group type: EXPERIMENTAL
Intervention: Removal of falls risk screening tool from falls risk assessment programme
Number of subjects: 0
Study 32945020 — intervention group
Group type: COMPARATOR
Intervention: Control condition with falls risk screening tool
Number of subjects: 0
Study 32945020 — intervention group
Group type: EXPERIMENTAL
Intervention: Removal of falls risk screening tool
Number of subjects: 0
Study 36430049 — intervention group
Group type: EXPERIMENTAL
Intervention: Maitland mobilization and routine rehabilitation (EG)
Number of subjects: 48
Study 36430049 — intervention group
Group type: COMPARATOR
Intervention: Routine rehabilitation (CG)
Number of subjects: 48
Study 36430049 — intervention group
Group type: COMPARATOR
Intervention: Sham mobilization and routine rehabilitation (SG)
Number of subjects: 48
Study 34208055 — intervention group
Group type: EXPERIMENTAL
Intervention: Epinephrine group (125 µg epinephrine)
Number of subjects: 130
Study 34208055 — intervention group
Group type: COMPARATOR
Intervention: Control group (no epinephrine)
Number of subjects: 130
Study 34208055 — intervention group
Group type: EXPERIMENTAL
Intervention: Epinephrine group
Number of subjects: 130
Study 32627570 — intervention group
Group type: EXPERIMENTAL
Intervention: Multi-component communication intervention including caregiver training and a speech-generating device
Number of subjects: 68
Study 35329374 — intervention group
Group type: EXPERIMENTAL
Intervention: Two active school-based interventions
Number of subjects: 1974
Study 35329374 — intervention group
Group type: COMPARATOR
Intervention: Waiting-list control condition
Number of subjects: 1974
Study 34062828 — intervention group
Group type: EXPERIMENTAL
Intervention: High-intensity resistance exercise training (HIRT) group (n = 21)
Number of subjects: 43
Study 34062828 — intervention group
Group type: COMPARATOR
Intervention: Control group (CG, n = 22)
Number of subjects: 43
Study 34928408 — intervention group
Group type: EXPERIMENTAL
Intervention: HP‐TDR (high-protein total diet replacement)
Number of subjects: 43
Study 34928408 — intervention group
Group type: COMPARATOR
Intervention: CON (control diet)
Number of subjects: 43
Study 32271243 — intervention group
Group type: EXPERIMENTAL
Intervention: sirolimus‐eluting Orsiro stent
Number of subjects: 2525
Study 32271243 — intervention group
Group type: COMPARATOR
Intervention: biolimus‐eluting Nobori stent
Number of subjects: 2525
Study 36259380 — intervention group
Group type: EXPERIMENTAL
Intervention: Cabozantinib (60 mg/day)
Number of subjects: 258
Study 36259380 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 258
Study 36259380 — intervention group
Group type: EXPERIMENTAL
Intervention: Cabozantinib
Number of subjects: 258
Study 35010526 — intervention group
Group type: COMPARATOR
Intervention: iSED group
Number of subjects: 245
Study 35010526 — intervention group
Group type: COMPARATOR
Intervention: iPA group
Number of subjects: 245
Study 36037322 — intervention group
Group type: EXPERIMENTAL
Intervention: Metacognitive Training (MCT)
Number of subjects: 34
Study 36037322 — intervention group
Group type: COMPARATOR
Intervention: Healthy living skills control group
Number of subjects: 34
Study 32143721 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral tranexamic acid (TXA) 1950 mg with sublingual misoprostol 800 mcg
Number of subjects: 258
Study 32143721 — intervention group
Group type: COMPARATOR
Intervention: Placebo with sublingual misoprostol 800 mcg
Number of subjects: 258
Study 32143721 — intervention group
Group type: EXPERIMENTAL
Intervention: Both TXA and placebo groups
Number of subjects: 258